• Active, not recruiting

NCT03836053: Phase 1b - AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma AMG420

Updated: Sep 2

AMG 420


AMG420

To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.


Sponsor

Amgen


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT03836053


Official Title: A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma

First Posted : February 11, 2019


Click here for details on ClinicalTrials.gov

 

Pacanalotamab - ( AMG 420 ) - ( BI 836909 )

 

Pacanalotamab

AMG 420

BI 836909

 

- New York: Memorial Sloan-Kettering Cancer Center New York

- Massachusetts: Massachusetts General Hospital Boston

- North Carolina: Wake Forest Baptist Health Winston-Salem

 

Locations

United States, Illinois

United States, Massachusetts

United States, New York

United States, North Carolina

Australia, New South Wales

Australia, Victoria

Europe

Belgium

Switzerland

Asia

Japan





Posts Archive